RNA - Avidity Corp Enterprise Value

Brandmark of Avidity Corp (RNA)

Avidity Biosciences (RNA) specializes in developing innovative nucleic acid-based medicines. This price chart shows that Avidity Biosciences (RNA) shares reflect an Enterprise Value of -83.21. Shareholder confidence is driven by prudent capital management and successful trials. The business is decoupled from economic cycles, relying solely on medical breakthroughs. The current priority is expanding the pipeline of myopathy therapies and launching commercial sales.

RNA (Avidity Corp) Total Company Value history from 11/23/2025 to 10/27/2026

Avidity Biosciences (RNA) - metric breakdowns and financial figures

- price and consensus price forecast:
Share Price Avidity Biosciences Inc|RNA - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Avidity Biosciences|RNA - Enterprise Value
- book capitalization data:
Equity per Share Avidity Biosciences|RNA - Company Book Value|Capitalization to Book Value Ratio aviditybiosciences.com|RNA - Company Total Assets
- debt and liquidity data:
Total Debt to Capital Avidity Biosciences|RNA - Long-Term Debt to Capital|Short-Term Debt to Capital aviditybiosciences.com|RNA - Company Total Debt|Debt to Book Capitalization Ratio Avidity Biosciences
Analysis of all company metrics:RNA (Avidity Biosciences Inc)
Original product of Avidity Biosciences

Enterprise Value (EV) represents the total capital combining market capitalization and net debt, reflecting the actual cost of a full business buyout. By analyzing the projected enterprise value, an investor assesses the real price of Avidity Biosciences assets, where a high valuation is justified by the unique AOC platform and a patent advantage in the targeted RNA drug delivery segment.

Competing companies

Business Value Tempus AI TEM|Qiagen Group - Enterprise Value|IONS - Enterprise Value|Enterprise Value Repligen Corporation|CRSP (crisprtx.com) - Business Value|Total Company Value GeneDx (WGS)|Business Value Ultragenyx Pharmaceutical Inc.|Enterprise Value BEAM|Enterprise Value Sarepta Corp (SRPT)|Enterprise Value TWST (Twist Bioscience)|TXG - Enterprise Value|NTLA - Real Price to Acquire Entire Company|STOK - Total Company Value|BioLife Corp - Enterprise Value|Wave Pharma (WVE) - Company Buyout Price|Enterprise Value Maze Therapeutics Inc (MAZE)|Business Value sionnatx.com|PRME (Prime Medicine) - Enterprise Value|Company Buyout Price Taysha Gene Therapies Inc TSHA|Real Price to Acquire Entire Company uniQure Corp (QURE)|MGTX - Aggregate Business Value|RGNX (REGENXBIO Inc.) - Real Price to Acquire Entire Company|solidbio.com (SLDB) - Total Enterprise Value|Real Price to Acquire Entire Company Ocugen OCGN|Pacific Biosciences of California, Inc. (PACB) - Value Adjusted for Debt and Cash|Enterprise Value Benitec|Total Company Value Design Corp|RCKT (Rocket Pharmaceuticals) - Enterprise Value|Company Buyout Price FDMT (4dmoleculartherapeutics.com)|LXEO: Total Company Value|Korro Bio Inc. - Total Enterprise Value|Total Company Value EDIT (Editas)|SLN - Company Buyout Price|PRQR (proqr.com) - Enterprise Value|Codexis (CDXS) - Real Price to Acquire Entire Company|SGMO: Enterprise Value|Company Buyout Price Nautilus Biotechnology Inc|Metagenomi, Inc - Enterprise Value|Total Enterprise Value DTIL (precisionbiosciences.com)|GBIO - Total Company Value|Business Value boundlessbio.com BOLD|XCUR: Enterprise Value|IMNN - Real Price to Acquire Entire Company|Enterprise Value PHIO|MBIO (Mustang Bio) - Total Enterprise Value|RNAZ: Total Company Value|Company Buyout Price BNGO|Applied DNA Sciences, Inc. (APDN) - Total Company Value|Value Adjusted for Debt and Cash BLUE (bluebird bio Inc.)|IPA - Total Company Value|Business Value Omega Therapeutics Corp OMGA|Singular Genomics Systems - Enterprise Value|RGLS - Enterprise Value|Enterprise Value Syros Pharmaceuticals, Inc.|TBIO (Telesis Bio Inc.) - Business Value|Total Company Value TRACON (TCON)|Business Value Unity Biotechnology, Inc